Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Glioblastoma

    New York, NY

    Search
    Glioblastoma
    New York, NY
    Show Map
    Map View
    New York, NY
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      94 Glioblastoma Trials near New York, NY

      Power is an online platform that helps thousands of Glioblastoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      IDH305 for Advanced Cancer

      New York, New York
      A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiac, Respiratory, Gastrointestinal, Others

      166 Participants Needed

      CTO + Temodar® for Glioblastoma

      New York, New York
      The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid tumors; in combination with oral Temodar® in patients with glioblastoma or other recurrent malignant gliomas; or in combination with oral Temodar® and radiation therapy in patients with newly diagnosed glioblastoma or other malignant gliomas.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Congestive Heart Failure, Uncontrolled Hypertension, Active Infection, Unstable Diabetes, Others
      Must Not Be Taking:CYP3A4 Inhibitors/inducers

      100 Participants Needed

      Selinexor + Temozolomide for Recurrent Glioblastoma

      New York, New York
      This trial tests selinexor with temozolomide for patients whose brain cancer has returned. Selinexor blocks a protein that helps cancer cells grow, and temozolomide damages their DNA to kill them or stop their growth. Temozolomide is a DNA methylating drug currently used as a first-line treatment in glioblastoma therapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Pregnant, Severe COVID-19, Others
      Must Not Be Taking:Bevacizumab, Dacarbazine

      97 Participants Needed

      TNG456 + Abemaciclib for Solid Tumors

      New York, New York
      This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Infection, Cardiovascular Disease, Others
      Must Not Be Taking:PRMT5 Inhibitors, MAT2A Inhibitors, CDK4/6 Inhibitors

      191 Participants Needed

      Debio 0123 + Temozolomide for Glioblastoma

      New York, New York
      This trial is testing a new drug called Debio 0123 combined with standard treatments for adults with aggressive brain cancer. It aims to find the best dose, ensure safety, and check if it works better than current treatments.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancies, LVEF Below 55%, Others
      Must Be Taking:Anti-epileptic Drugs

      116 Participants Needed

      Berubicin for Glioblastoma

      New York, New York
      This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Uncontrolled Hypertension, Others
      Must Not Be Taking:Bevacizumab, Lomustine, Others

      210 Participants Needed

      177Lu-PSMA-617 for Brain Cancer

      New York, New York
      The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Chronic Kidney Disease, Viral Hepatitis, Others
      Must Be Taking:Dexamethasone

      20 Participants Needed

      LY3410738 for Solid Tumors

      New York, New York
      This trial is testing a new oral drug called LY3410738 in patients with advanced solid tumors that have specific genetic mutations. The drug works by blocking abnormal enzymes to potentially stop or slow cancer growth.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active CNS Metastases, Uncontrolled Cardiac Disease, Others
      Must Not Be Taking:Strong CYP3A4 Inhibitors, P-gp Inhibitors

      200 Participants Needed

      TNG908 for Solid Tumors

      New York, New York
      This trial is testing TNG908, an oral drug, in patients with advanced or metastatic solid tumors that have an MTAP deletion. The drug works by blocking a protein that helps these specific cancer cells grow. The study will see if this treatment can help slow down or stop the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Liver Disease, Cardiovascular, Others
      Must Not Be Taking:Antiretrovirals

      192 Participants Needed

      CLR 131 for Pediatric Cancer

      New York, New York
      This trial is testing CLR 131, a radioactive medicine designed to target and kill cancer cells. It is aimed at children, adolescents, and young adults whose cancers have returned or do not respond to other treatments. CLR 131 works by delivering radiation directly to the cancer cells, reducing harm to healthy cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:2 - 25

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, I-131 Dose > 54 MCi/kg, Others
      Must Not Be Taking:Antitumor, Investigational

      30 Participants Needed

      Abemaciclib Combination Therapy for Neuroblastoma

      New York, New York
      The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:< 21

      Key Eligibility Criteria

      Disqualifiers:Transplant, Pregnancy, Infections, Others
      Must Not Be Taking:CYP3A Inhibitors, UGT1A1 Inhibitors

      47 Participants Needed

      Repotrectinib for Solid Tumors in Young Patients

      New York, New York
      Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:0 - 25

      Key Eligibility Criteria

      Disqualifiers:Neuroblastoma, Active Infections, Cardiac Issues, Others
      Must Not Be Taking:Strong CYP3A4 Inhibitors

      75 Participants Needed

      Selinexor for Pediatric Solid Tumors or Brain Tumors

      New York, New York
      This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or central nervous system (CNS) tumors that have come back (recurrent) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:12 - 21

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      59 Participants Needed

      M3554 for Solid Tumors

      New York, New York
      The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      52 Participants Needed

      BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

      New York, New York
      BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Resistant Mutations, Interstitial Lung Disease, Others
      Must Be Taking:EGFR TKIs

      200 Participants Needed

      BPM31510 + Vitamin K1 for Glioblastoma

      New York, New York
      This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Cerebral Hemorrhage, Cardiac History, Coagulopathies, Others
      Must Not Be Taking:Anticoagulants, Digitalis, Antiangiogenics, Theophylline

      50 Participants Needed

      ST101 for Advanced Cancer

      New York, New York
      This trial tests a new drug, ST101, given to patients with advanced cancers who haven't responded to other treatments. The study aims to find the safest and most effective dose. It includes patients with specific types of breast cancer, melanoma, brain cancer, and prostate cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, CNS Metastases, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      125 Participants Needed

      GBM Vaccine for Glioblastoma

      New York, New York
      This trial is testing a new vaccine called VBI-1901 for patients whose brain cancer, glioblastoma, has returned. The vaccine aims to help the immune system recognize and fight the cancer cells. Researchers are checking if the vaccine is safe and finding the best dose to use.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Cancer History, Autoimmune, Others
      Must Not Be Taking:Immunosuppressants, Antivirals

      98 Participants Needed

      DSP-0390 for Brain Tumor

      Boston, Massachusetts
      This trial is testing a new drug called DSP-0390 in patients with a type of brain cancer that has returned after treatment. The goal is to see if this drug can help stop or slow down the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Early Phase 1

      Key Eligibility Criteria

      Disqualifiers:Multifocal Disease, Metastasis, Cardiovascular, Others
      Must Be Taking:Antiepileptics, Corticosteroids

      39 Participants Needed

      Immunotherapy Before and After Surgery for Brain Tumor

      Hackensack, New Jersey
      This trial studies the effects of nivolumab, an immunotherapy drug, in children and young adults with severe brain cancer that has returned or worsened. The drug helps the immune system fight the cancer and may prevent it from growing.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:6 - 25

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Brainstem Tumor, Active Infection, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      20 Participants Needed

      Why Other Patients Applied

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Glioblastoma Trial

      PARP Inhibitor + Temozolomide for Brain Cancer

      Hackensack, New Jersey
      This trial studies the safety and best dose of BGB-290 and temozolomide in treating young people with a specific type of brain tumor. BGB-290 blocks enzymes needed for tumor growth, while temozolomide kills or stops cancer cells from growing. The goal is to find out if this combination works better for these patients.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:13 - 39

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Other Malignancy, Bleeding Disorder, Others
      Must Not Be Taking:PARP Inhibitors, Anticoagulants

      78 Participants Needed

      ASP8374 + Cemiplimab for Recurrent Brain Cancer

      New York, New York
      This trial is testing the safety and effectiveness of combining two drugs, ASP8374 and cemiplimab, for people with recurrent brain cancer. The study aims to find the best dose and see if the combination helps before surgery. The drugs work by boosting the immune system to fight cancer cells. Cemiplimab has been previously tested in combination with other treatments for severe cancers.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Active Infection, Autoimmune, Others
      Must Not Be Taking:Anti-VEGF, Immunosuppressants

      14 Participants Needed

      Personalized Vaccine + TTFields for Glioblastoma

      The Bronx, New York
      The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields). The study is designed to determine whether this treatment combination is well tolerated and safe.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Disease Progression, Implanted Devices, HIV/AIDS, Others
      Must Be Taking:Temozolomide, Dexamethasone

      13 Participants Needed

      Eflornithine + Temozolomide for Glioblastoma

      New York, New York
      The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Recurrent Cancer, Cardiac Disease, Others
      Must Be Taking:Temozolomide

      66 Participants Needed

      Cobolimab + Dostarlimab for Cancer

      Hackensack, New Jersey
      The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:0 - 21

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled CNS Involvement, Cardiovascular Disease, Respiratory Disease, Others
      Must Not Be Taking:Immunosuppressants, Systemic Steroids

      83 Participants Needed

      TROP2 ADC + Anti-PD-1 for Solid Cancer

      Hackensack, New Jersey
      This trial tests a new cancer treatment that targets and kills cancer cells directly and boosts the immune system. It is for patients with advanced cancers that don't respond to usual treatments. The study aims to find the best dose and safety of this new treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active CNS Metastases, Leptomeningeal Disease, Others
      Must Not Be Taking:Systemic Steroids

      300 Participants Needed

      Optune Device for Brain Cancer

      Hackensack, New Jersey
      This trial tests if a device using electric fields, combined with two drugs, can help children with aggressive brain tumors that have returned after treatment. The device stops cancer cells from growing, while the drugs damage the cancer cells and cut off their blood supply. This approach has been tested for many years and is used for various types of cancer, combining electric pulses with chemotherapy drugs to increase their effectiveness.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:5 - 21

      Key Eligibility Criteria

      Disqualifiers:Age, Pacemaker, Pregnancy, Others
      Must Not Be Taking:Corticosteroids, Anti-cancer Drugs

      7 Participants Needed

      Ramipril for Memory Loss in Glioblastoma Patients

      Lake Success, New York
      This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      75 Participants Needed

      Immunotherapy for Brain Tumor

      Summit, New Jersey
      This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden). Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Diseases, Active Malignancy, Others
      Must Not Be Taking:Checkpoint Inhibitors, Bevacizumab

      37 Participants Needed

      Rhenium Liposome Treatment for Brain Cancer

      Manhasset, New York
      This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Cardiac Arrhythmias, Others
      Must Be Taking:Antiepileptics, Corticosteroids

      55 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Glioblastoma clinical trials in New York, NY pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Glioblastoma clinical trials in New York, NY work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Glioblastoma trials in New York, NY 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New York, NY for Glioblastoma is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New York, NY several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Glioblastoma medical study in New York, NY?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Glioblastoma clinical trials in New York, NY?

      Most recently, we added 177Lu-PSMA-617 for Brain Cancer, G207 + Radiation for Pediatric Brain Tumor and ABBV-637 + ERAS-801 for Glioblastoma to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in New York

      Anxiety Clinical Trials in New York

      Schizophrenia Clinical Trials in New York

      ADHD Clinical Trials in New York

      Bipolar Disorder Clinical Trials in New York

      Multiple Sclerosis Clinical Trials in New York

      Autism Clinical Trials in New York

      Treatment Resistant Depression Clinical Trials in New York

      Borderline Personality Disorder Clinical Trials in New York

      Social Anxiety Disorder Clinical Trials in New York

      Parkinson's Disease Clinical Trials in New York

      Alzheimer's Disease Clinical Trials in New York

      By Location

      Clinical Trials near New York, NY

      Clinical Trials near Rochester, NY

      Clinical Trials near Bronx, NY

      Clinical Trials near The Bronx, NY

      Clinical Trials near Buffalo, NY

      Clinical Trials near Brooklyn, NY

      Clinical Trials near Syracuse, NY

      Clinical Trials near Albany, NY

      Clinical Trials near Stony Brook, NY

      Clinical Trials near Manhasset, NY

      Clinical Trials near New Hyde Park, NY

      Clinical Trials near Mineola, NY

      Other People Viewed

      By Subject

      15 Leiomyosarcoma Trials near New York, NY

      49 Glioblastoma Trials near Philadelphia, PA

      88 Breast Cancer Trials near New York, NY

      21 Glioblastoma Trials near Tampa, FL

      71 Glioblastoma Trials near Houston, TX

      26 Glioblastoma Trials near Dallas, TX

      43 Glioblastoma Trials near Phoenix, AZ

      13 Obsessive Compulsive Disorder Ocd Trials near New York, NY

      181 Clinical Trials near Ithaca, NY

      Top Prostate Cancer Clinical Trials near New York, NY

      Top Clinical Trials near New York

      Top Recurrent Glioblastoma Clinical Trials

      By Trial

      Temozolomide + Veliparib for Glioblastoma

      SVZ Radiation + Temozolomide for Glioblastoma

      Stem Cell Rescue Therapy for Glioblastoma

      High-Dose Radiation + Temozolomide for Glioblastoma

      ITI-1001 for Glioblastoma

      NG101m Adjuvant Therapy for Glioblastoma

      Debio 0123 + Temozolomide for Glioblastoma

      Cediranib + Olaparib vs Bevacizumab for Recurrent Glioblastoma

      Liposomal Curcumin + RT/TMZ for Brain Tumor

      Dendritic Cell Vaccine + Standard Therapy for Glioblastoma

      Fluoxetine + Chemotherapy for Brain Cancer

      SurVaxM Vaccine for Brain Cancer

      Related Searches

      Top Lung-cancer Clinical Trials near Anaheim, CA

      Top Lung-cancer Clinical Trials near Dallas, TX

      Top Lung-cancer Clinical Trials near Las Vegas, NV

      WET + EFST for PTSD During Pregnancy

      Brain Stimulation for Depression

      Top Clinical Trials near Colton, CA

      ABBV-787 for Acute Myeloid Leukemia

      AZD5004 for Kidney Failure

      Osavampator for Depression

      LY4175408 for Cancer

      Radiation Therapy for Recurrent Brain Tumors

      Top Cataract Clinical Trials